我們已在上線！進一步了解

TriSalus Life Sciences

TLSI

市值 US$2.24億

3.63 USD

-0.27

6.92%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

3.66

+0.03

0.83%

1天

-6.92%

5天

-11.46%

1個月

-26.37%

3個月

-16.74%

6個月

-19.15%

今年迄今

-40.49%

1年

-23.58%

5年

-63.41%

10年

-65.49%

關於： TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

員工： 102

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 30%

中性 60%

負面 10%

TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support

The U.S. Food and Drug Administration (FDA) on Wednesday granted 510(k) clearance for TriSalus Life Sciences Inc.'s (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio.

TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday

Shares of TriSalus Life Sciences Inc (NASDAQ:TLSI) rose sharply after the company announced it received FDA 510(k) clearance for TriNav Advance.

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery™ (PEDD) portfolio. TriNav® Advance expands Tri.

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference.

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing the company's pressure-enabled delivery technology for solid-tumor treatments.

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

TriSalus Life Sciences Q2 Earnings Call Highlights

TriSalus Life Sciences NASDAQ: TLSI reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, representing projected growth of 19% to 26% over 2025.

TriSalus Life Sciences Q2 Earnings Call Highlights

Wasatch Micro Cap Fund Q2 2026 Contributors And Detractors

The leading contributor was Ambiq Micro, Inc. (AMBQ) , a designer of ultra-low power semiconductor solutions that went public in July of 2025. Suncrete's stock moved higher in the wake of strong first quarter revenue growth. TriSalus posted a significant miss on revenues and lowered guidance during the quarter, citing the impact of a Salesforce (CRM) reorganization and delayed FDA review of its next-generation device.

Wasatch Micro Cap Fund Q2 2026 Contributors And Detractors

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

TriSalus Life Sciences Reports Second Quarter 2026 Results

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our f.

TriSalus Life Sciences Reports Second Quarter 2026 Results

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings o.

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

查看新聞排名

價格圖表採用Lightweight Charts™實作